September 24, 2024
Currax Pharmaceuticals Unveils New Disease Awareness Campaign to “Quiet the Food Noise,” a Key Barrier for Individuals Seeking Weight Loss
Read moreAugust 27, 2024
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study
Read moreJuly 24, 2024
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
Read moreJanuary 25, 2024
Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial
Read moreOctober 19, 2023
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
Read moreMarch 6, 2023
Currax Files Lawsuit Against Found Health for False Marketing of Generic Equivalent of CONTRAVE®
Read moreAugust 30, 2022
One Size Does Not Fit All™: Currax Pharmaceuticals Launches New Campaign to Address Emotional Eating Challenges Faced by Individuals Seeking Weight Loss
Read moreJanuary 7, 2022
Currax Pharmaceuticals Appoints Michael Kyle, M.D., as Senior Vice President, Chief Medical Officer
Read moreOctober 26, 2021
Currax Pharmaceuticals Announces the Appointment of Ed Cinca to Senior Vice President, Global Marketing and Strategic Alliance Management
Read moreOctober 21, 2021